Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

Autor: Kimby, Eva1 (AUTHOR) eva@kimby.se, Östenstad, Björn2 (AUTHOR), Brown, Peter3 (AUTHOR), Hagberg, Hans4 (AUTHOR), Erlanson, Martin5 (AUTHOR), Holte, Harald2 (AUTHOR), Linden, Ola6 (AUTHOR), Johansson, Ann-Sofie5 (AUTHOR), Ahlgren, Tomas7 (AUTHOR), Wader, Karin8 (AUTHOR), Wahlin, Björn Engelbrekt1 (AUTHOR), Delabie, Jan9 (AUTHOR), Sundström, Christer10 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Sep2015, Vol. 56 Issue 9, p2598-2607. 10p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje